Abdominal pain atomoxetine

SSRIs ATOMOXETINE t plasma concentrations and risk of adverse effects (abdominal pain, vomiting, nausea, fatigue, irritability) Atomoxetine is a selective norepinephrine reuptake inhibitor, t plasma concentrations due to inhibition of CYP2D6 by fluoxetine and paroxetine (potent), fluvoxamine and sertraline (less potent) and escitalopram and citalopram (weak) Avoid concurrent use. The interaction is usually severe with fluoxetine and paroxetine... [Pg.177]

Placebo-controlled studies In a doubleblind, randomized, placebo-controlled study of the use of once-daily atomoxetine up to 1.8 mg/kg/day in 105 patients aged 6-16 years with ADHD, the most common treatment-emergent signs and symptoms were anorexia (atomoxetine 18% placebo 6%), somnolence (15% versus 9%), abdominal pain (13% versus 3%), and nausea (11% versus 3%) [52 ]. [Pg.5]

A retrospective cohort study of new atomoxetine users (n = 20,995) showed that the propensity-score adjusted hazard ratio for sudden death/ventricular arrhythmia was 0.41 (95% Cl 0.10-1.75), for stroke 1.30 (95% Cl 0.52-3.29), for myocardial infarction 0.56 (95% CLO.16-2.00) and 0.92 for stroke/myocardial 0.75 infarction (95% CEO.44-1.92) [2 ]. For atomoxetine, the most commonly reported ADRs in >5% of patients using the agent were decreased appetite, weight loss, suicidal thoughts in children, abdominal pain, erectile dysfunction, headache, insomnia, nausea, xerostomia and tachycardia [6 ] [7 j [36 j [37 ]. [Pg.7]

Big Chemical Encyclopedia